The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria
- Registration Number
- NCT00858299
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
This study is a multicenter, prospective, interventional study. It does not have a control group. All participants will receive 160 mg valsartan for 8 weeks. Among them, the patients with persistent proteinuria (defined as proteinuria more than 1 g/g after 8 weeks treatment of valsartan) will receive 320 mg valsartan for further 16 weeks. Participants who did not receive any ACEI or ARB previously will have a titration period for 4 weeks (80 mg for 4 weeks, 160 mg for 4 weeks, and then 320 mg for 16 weeks).
The investigators will evaluate the change of urinary angiotensinogen excretion between at baseline, at 8 weeks, and 24 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
-
Chronic kidney disease patients with
- proteinuria of 1 - 10 g/day,
- stable and controlled blood pressure (100/60 mmHg - 160/100 mmHg),
- stable renal function with GFR ≥ 30 mL/min/ m2,
- diabetes or non-diabetes
- Uncontrolled diabetes (defined as HbA1c > 9.0%)
- Immunosuppressive treatment within 6 months
- Intractable edema
- Hyperkalemia (>5.5 mEq/L) or Hypokalemia (< 3.5 mEq/L)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description valsartan valsartan -
- Primary Outcome Measures
Name Time Method The percent change of urinary angiotensinogen excretion between at baseline and at 24 weeks after valsartan treatment. 4 weeks of screening periods + 24 weeks of treatment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Division of Nephrology, Samsung Medical Center
🇰🇷Seoul, Korea, Republic of